The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )
Status:
Unknown status
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is a 12 week double-blind randomized placebo controlled trial in which 30 patients with
very early SSc, fulfilling the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) criteria
(9) will be randomized in a 2:1 fashion to receive intravenous methylprednisolone or placebo.
Three-day treatment courses are given at week 0, week 4 and week 8. The final assessment is
at week 12, and patients will be followed up to one year after baseline